Renaissance Technologies’s Addex Therapeutics ADXN Stock Holding History

Renaissance Technologies’s Portfolio ADXN Stock Details ADXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,095	Closed	-$14K	–	3928
2022 Q4	$14K	Sell	1,095 -382	-26%	-$5.64K	﹤0.01%	4012
2022 Q3	$24K	Buy	+1,477	New	+$33K	﹤0.01%	3871

Other funds holding ADXN

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies's ADXN Position: Q1 2023 in Review

Renaissance Technologies sold out of Addex Therapeutics (ADXN) in Q1 2023, closing a stake of 1,095 shares — an estimated $14K sold.

Renaissance Technologies first reported a position in ADXN in Q3 2022 and held it in 2 quarters. The position peaked at $24K in Q3 2022. 7 funds tracked by Wall St. Rank hold ADXN as of Q1 2023.

Renaissance Technologies reported no remaining Addex Therapeutics position as of Q1 2023 after selling out during the quarter.
Renaissance Technologies sold 1,095 Addex Therapeutics shares in Q1 2023, an estimated $14K.
Renaissance Technologies first reported a position in Addex Therapeutics in Q3 2022 and held it in 2 quarters.
Renaissance Technologies's Addex Therapeutics position peaked at $24K in Q3 2022.
7 funds tracked by Wall St. Rank held Addex Therapeutics as of Q1 2023.

Based on Renaissance Technologies's 13F filing for Q1 2023, filed 12 May 2023.